Author

D. Selimoglu-Buet

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

E. Solary· 3 shared A. Imanci· 2 shared A. Renneville· 2 shared f. Porteu· 2 shared L. Laplane· 2 shared M. Morabito· 2 shared N. Droin· 2 shared R. Chelbi· 2 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

E. Solary

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

CXCL8 secreted by immature granulocytes inhibits wildtype hematopoiesis in chronic myelomonocytic leukemia

P. Deschamps, M. Wacheux, A. Gosseye, M. Morabito, A. Pages, A.-M. Lyne, A. Alfaro, P. Rameau, A. Imanci, R. Chelbi, V. Marchand, A. Renneville, M. M. Patnaik, V. Lapierre, B. Badaoui, , D. Selimoglu-Buet

The paper identifies CXCL8 secreted by immature granulocytes as a factor inhibiting wildtype hematopoiesis in CMML, suggesting CXCL8 blockade could slow disease progression.

bioRxiv · Mar 8, 2024Cancer Biology

Targeting Heterochromatin Eliminates Malignant Stem Cells in Chronic Myelomonocytic Leukemia Through Reactivation of Retroelements and Innate Immune pathways

D. Hidaoui, A. Porquet, R. Chelbi, M. Bohm, A. Polizou, V. Alcazer, S. Depil, A. Imanci, M. Morabito, A. Renneville, D. Selimoglu-Buet, S. Thepot, R. Itzykson, L. Laplane, N. Droin, , F. PORTEU

This study shows that combining DNA hypomethylating agents with H3K9me2 inhibitors reactivates immune pathways and eliminates malignant stem cells in CMML by targeting heterochromatin disorganization.

bioRxiv · Feb 2, 2024Cancer Biology

CDKN1A is a target for phagocytosis-mediated cellular immunotherapy in acute leukemia

A. ALLOUCH, L. VOISIN, Y. ZHANG, R. SYED, Y. LECLUSE, J. CALVO, D. Selimoglu-Buet, S. DE BOTTON, F. LOUACHE, F. PFLUMIO, E. SOLARY, j.-l. PERFETTINI

This study shows that overexpressing CDKN1A in macrophages enhances their ability to phagocytose leukemic cells, leading to pro-inflammatory reprogramming and improved survival in mouse models.

bioRxiv · Jan 18, 2022Immunology